Hemanext raised $19.98 million to develop transfusion technologies that improve red blood cell quality for patients with rare blood disorders like Myelodysplastic Syndrome (MDS) and Sickle Cell Disease (SCD), using its Hemanext ONE RBC Processing and Storage System to mitigate storage-related deterioration.
